ロード中...
Chemoprevention of Hormone Receptor-Negative Breast Cancer: New Approaches Needed
Results from clinical trials have demonstrated that it is possible to prevent estrogen-responsive breast cancers by targeting the estrogen receptor with selective estrogen receptor modulators (SERMs) (tamoxifen, raloxifene, or lasofoxifene) or with aromatase inhibitors (AIs) (anastrozole, letrozole,...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2011
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3415693/ https://ncbi.nlm.nih.gov/pubmed/21253797 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/978-3-642-10858-7_13 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|